06:53 EST BioNTech sees FY24 revenue EUR3.0B, consensus $4.17B
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BNTX:
- BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
- Carnival upgraded, PayPal downgraded: Wall Street’s top analyst calls
- BioNTech initiated with a Perform at Oppenheimer
- Florida surgeon general calls for halt to use of mRNA Covid-19 vaccines
- BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer